Rocket Pharmaceuticals (RCKT) EPS (Weighted Average and Diluted) (2019 - 2026)
Rocket Pharmaceuticals' (RCKT) quarterly EPS (Weighted Average and Diluted) came in at -$0.42 in Q1 2026, up 25.0% year-on-year from -$0.34 in Q1 2025, and down 10.53% quarter-over-quarter from -$0.38 in Q4 2025.
Rocket Pharmaceuticals (RCKT) EPS (Weighted Average and Diluted) (2019 - 2026) Analysis & Trends
Rocket Pharmaceuticals has disclosed EPS (Weighted Average and Diluted) across 8 years of filings, most recently posting -$0.42 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.42, up 25.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.87 (up 28.9% YoY), and the FY2025 annual result was -$2.01, up 26.37% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.42 for Q1 2026 at Rocket Pharmaceuticals, down from -$0.38 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.38 in Q4 2025 to a low of -$0.89 in Q4 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.67 (2022), against an average of -$0.67.
- Across the five-year window, EPS (Weighted Average and Diluted) slumped 50.91% in 2022 and soared 38.71% in 2025, its largest moves.
- Rocket Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.89 in 2022, then soared by 30.34% to -$0.62 in 2023, then changed by 0.0% to -$0.62 in 2024, then jumped by 38.71% to -$0.38 in 2025, then fell by 10.53% to -$0.42 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.42 (Q1 2026), -$0.38 (Q4 2025), and -$0.45 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 0.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -0.61 |
| 10 | Rocket Pharmaceuticals | 296.03 Mn | 296.03 Mn | - | -0.42 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.42 |
| Dec 31, 2025 | -0.38 |
| Sep 30, 2025 | -0.45 |
| Jun 30, 2025 | -0.62 |
| Mar 31, 2025 | -0.56 |
| Dec 31, 2024 | -0.62 |
| Sep 30, 2024 | -0.71 |
| Jun 30, 2024 | -0.74 |
| Mar 31, 2024 | -0.66 |
| Dec 31, 2023 | -0.62 |
| Sep 30, 2023 | -0.75 |
| Jun 30, 2023 | -0.82 |
| Mar 31, 2023 | -0.73 |
| Dec 31, 2022 | -0.89 |
| Sep 30, 2022 | -0.87 |
| Jun 30, 2022 | -0.83 |
| Mar 31, 2022 | -0.67 |
| Dec 31, 2021 | -0.68 |
| Sep 30, 2021 | -0.79 |
| Jun 30, 2021 | -0.55 |